Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · IEX Real-Time Price · USD
-0.46 (-2.01%)
At close: Apr 16, 2024, 4:00 PM
-1.12 (-4.99%)
After-hours: Apr 16, 2024, 4:59 PM EDT

Company Description

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.

Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.

The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases.

In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis.

Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases.

The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019.

Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Kyverna Therapeutics, Inc.
Kyverna Therapeutics logo
Country United States
Founded 2018
IPO Date Feb 8, 2024
Industry Biotechnology
Sector Healthcare
Employees 96
CEO Peter Maag, Ph.D.

Contact Details

5980 Horton Street, Suite 550
Emeryville, California 94608
United States
Phone (510) 626-8331

Stock Details

Ticker Symbol KYTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $22.00
CIK Code 0001994702
Employer ID 83-1365441
SIC Code 2836

Key Executives

Name Position
Dr. Peter Maag Ph.D. Chief Executive Officer and Director
Karen Walker Chief Technology Officer
Dr. James Chung M.D., Ph.D. Chief Medical Officer
Ryan Jones Chief Financial Officer
Dr. Tom Van Blarcom Ph.D. Senior Vice President and Head of Research
Portia Serame Vice President of Human Resources
Dr. Dominic Borie M.D., Ph.D. President of Research and Development
Devin Murray Senior Vice President of Partnerships and Alliances

Latest SEC Filings

Date Type Title
Mar 26, 2024 10-K Annual Report
Mar 26, 2024 8-K Current Report
Feb 22, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 20, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 12, 2024 8-K Current Report
Feb 8, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 8, 2024 424B4 Prospectus
Feb 8, 2024 CERT Certification by an exchange approving securities for listing
Feb 7, 2024 EFFECT Notice of Effectiveness